Floatz logo

Epirubicin

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Seda S. ToluPhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Primary Mediastinal Large B-cell Lymphoma (PMBCL) cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Seda S. Tolu
Phase 2BB
Wztl-002 Car T-Cells
Malaghan Institute of Medical Research
Phase 2CCC
il-15
Medical College of Wisconsin
Phase 1/2CC
tc011
TICAROS Co., Ltd.
Phase 1/2CC
Rhil-7
Medical College of Wisconsin
Phase 1/2CC

View all 13 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →